Acumen Pharmaceuticals Inc (ABOS)
2.55
-0.09
(-3.41%)
USD |
NASDAQ |
Jun 17, 13:13
Acumen Pharmaceuticals Research and Development Expense (Quarterly): 12.45M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.45M |
| December 31, 2023 | 13.29M |
| September 30, 2023 | 11.18M |
| June 30, 2023 | 9.133M |
| March 31, 2023 | 8.713M |
| December 31, 2022 | 10.75M |
| September 30, 2022 | 8.309M |
| June 30, 2022 | 7.321M |
| March 31, 2022 | 5.985M |
| Date | Value |
|---|---|
| December 31, 2021 | 5.673M |
| September 30, 2021 | 1.80M |
| June 30, 2021 | 2.254M |
| March 31, 2021 | 2.578M |
| December 31, 2020 | 1.026M |
| September 30, 2020 | 2.994M |
| June 30, 2020 | 1.927M |
| March 31, 2020 | 2.05M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.026M
Minimum
Dec 2020
13.29M
Maximum
Dec 2023
6.319M
Average
5.985M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Accuray Inc | 10.91M |
| Kezar Life Sciences Inc | 17.17M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 0.904M |